Quanrui Jiang

Dr. Quanrui Jiang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2022 in Trials
Verified
Journal Article
Open access
PDF file
XFXiang Feng
Xiang Feng
QJQuanrui Jiang
Quanrui Jiang
YZYuxing Zhang
Yuxing Zhang
TLTao Li
Tao Li
WWWei Wei
Wei Wei
JLJiangshan Li
Jiangshan Li
Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by repetitive stereotypical behavior and communication deficits. Currently, it lacks a specific clinical treatment method. Pediatric Tuina is a recent therapy in traditional Chinese medicine (TCM) and has been used to treat children with ASD. Nonetheless, it remains uncommon given the lack of large-scale evidence-based medical studies. This study aims to compare the efficacy of Tuina and conventional treatment in children with ASD. Methods: Eligible children will be randomly assigned to either the pediatric Tuina plus conventional treatment group or to the conventional treatment alone group based on a random table at a ratio of 1:1. The effectiveness of the Tuina intervention for ASD will be evaluated by a third-party organization. The pre- and post-intervention scores on the Childhood Autism Rating Scale comprised the primary outcome, whereas pre- and post-intervention scores on the Autism Treatment Evaluation Checklist were the secondary outcomes to assess improvement in symptoms. Baseline values of the participants will be determined at the time of registration. Outcomes will be evaluated after the 30th treatment session. The follow-up period will last for 6 months after treatment. Discussion: This study will evaluate the effectiveness and safety of Tuina in the treatment of ASD. The results of this study could provide reliable evidence to improve the management of patients with ASD. Trial registration: Chinese Clinical Trial Registry (CHICTR), ChiCTR2000040452. Registered on 28 November 2020.

18 September 2018 in Journal of Acupuncture and Tuina Science
Verified
Journal Article
Closed access
PDF file
WLWu Li
Wu Li
QJQuanrui Jiang
Quanrui Jiang
KAKun AI
Kun AI
XLXiao-Wei Liu
Xiao-Wei Liu
JYJun Yu
Jun Yu
JLJiangshan Li
Jiangshan Li

1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
LWLiangbing Wu
Liangbing Wu
JDJian Dai
Jian Dai
YWYongzheng Wei
Yongzheng Wei
QJQuanrui Jiang
Quanrui Jiang
RHRenkun Huang
Renkun Huang
WLWei Lu
Wei Lu
Objective: Eczema is a common inflammatory skin disease that severely affects patients’ daily life and work, necessitating effective intervention. Medicated thread moxibustion of Zhuang medicine (MTMZM), an integral part of Chinese medicine, is also a component of complementary and alternative medicine, demonstrating promising therapeutic effects. However, its mechanism in treating eczema remains unknown. Therefore, this study investigated the efficacy and mechanism of MTMZM on skin lesions and p38/NF‐κB and JAK1‐STAT6 pathway in eczema rats. Methods: Forty‐eight male Sprague‐Dawley (SD) rats were randomly divided. Nine of them were assigned to the normal group, while the remaining 39 rats were selected for the subsequent eczema model establishment process. In total, 7% DNCB acetone olive oil solution was used to establish eczema model. Successful modeling rats were randomly divided into three groups with 13 rats each: model group, western medicine group (WM group), and MTMZM group. Normal group and model group received no treatment. MTMZM group received MTMZM treatment on the Ashi point (skin lesions in eczema) and WM group received positive drug Pevisone cream. The eczema severity index (ESI) in rats was scored before intervention and during the first and second weeks of intervention. After intervention, samples were taken from rats’ back lesions (taking normal skin in the same area from normal group). After sampling, the skin thickness difference (STD) with normal skin and diseased skin lesions was measured. HE staining was used to observe the tissue morphology of skin lesions. Western blot was used to detect JAK1, p‐JAK1, STAT6, p‐STAT6, NF‐κB p65, p‐NF‐κB p65, and p‐p38 protein content in skin lesions; the serum content of interleukin (IL)‐1β, tumor necrosis factor‐α (TNF‐α), and IL‐4 were detected by ELISA. Results: (1) Compared with normal group, model group showed dermal necrosis and inflammatory cell infiltration under light microscopy. The ESI and STD increased ( p < 0.05). JAK1, p‐JAK1, STAT6, p‐STAT6, NF‐κB p65, p‐NF‐κB p65, and p‐p38 protein content in skin lesion increased( p < 0.05). The serum content IL‐1β, TNF‐α, and IL‐4 increased ( p < 0.05). (2) Compared with model group, MTMZM group and WM group showed significant improvement in pathological changes. The ESI and STD decreased ( p < 0.05). NF‐κB p65, p‐NF‐κB p65, p‐p38, JAK1, p‐JAK1, STAT6, and p‐STAT6 content ( p < 0.05) decreased. The serum content IL‐1β, TNF‐α, and IL‐4 decreased ( p < 0.05). (3) Compared with WM group, MTMZM group showed visible neovascularization under light microscopy. The ESI and STD decreased ( p < 0.05). There was no significant difference in p‐p38, p‐NF‐κB p65, JAK1, p‐JAK1, STAT6, and p‐STAT6 content ( p > 0.05), as well as in IL‐4 content ( p > 0.05). The serum content IL‐1β and TNF‐α increased ( p < 0.05). Conclusion: MTMZM can effectively relieve eczema skin lesions, which may be related to the inhibition of p38/NF‐κB and JAK1‐STAT6 pathways.

31 January 2022
Verified
Report
Open access
XFXiang Feng
Xiang Feng
KLKeshang Li
Keshang Li
QJQuanrui Jiang
Quanrui Jiang
YZYuxing Zhang
Yuxing Zhang
ZGZhichao Gong
Zhichao Gong
JLJiangshan Li
Jiangshan Li
Review question / Objective: This study will help patients recover better, provide clinical evidence for practitioners, and promote the use of TCM in ASD interventions. Condition being studied: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social communication and/or social interaction as well as restrictive and/or repetitive behaviors. TCM has been clinically practiced in the intervention of ASD, especially in mainland China where studies have shown promising efficacy. However, it remains to be further explored and elaborated. Therefore, the purpose of this study was to evaluate the effectiveness and safety of conventional treatment-based TCM intervention modalities for ASD.